Rating Change: How Will NuVasive (NUVA) Stock React To Aegis Capital New Rating Coverage?

November 30, 2016 - By Hazel Jackson

Rating Change: How Will NuVasive (NUVA) Stock React To Aegis Capital New Rating Coverage?

Why Aegis Capital Gives NuVasive (NUVA) $72.0 Price Target

Analysts at Aegis Capital has started coverage on shares of NuVasive (NUVA) in a analysts note sent to investors on Wednesday, 30 November. The financial company set a “Buy” rating on the $3.36B market cap company.

About 61,360 shares traded hands. NuVasive, Inc. (NUVA) has risen 20.23% since April 27, 2016 and is uptrending. It has outperformed by 15.00% the S&P500.

Analysts await NuVasive, Inc. (NASDAQ:NUVA) to report earnings on February, 9. They expect $0.50 earnings per share, up 42.86% or $0.15 from last year’s $0.35 per share. NUVA’s profit will be $25.74 million for 32.64 P/E if the $0.50 EPS becomes a reality. After $0.40 actual earnings per share reported by NuVasive, Inc. for the previous quarter, Wall Street now forecasts 25.00% EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.51 in Q2 2016. Its up 0.40, from 1.11 in 2016Q1. The ratio is positive, as 37 funds sold all NuVasive, Inc. shares owned while 77 reduced positions. 45 funds bought stakes while 82 increased positions. They now own 50.84 million shares or 1.81% more from 49.94 million shares in 2016Q1.

Jacobs Levy Equity Mgmt has invested 0.01% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Citigroup, a New York-based fund reported 17,364 shares. Alliancebernstein Lp accumulated 81,522 shares or 0% of the stock. Puplava Fincl Services holds 0.66% or 19,741 shares in its portfolio. Ls Investment Advisors Limited Liability accumulated 2,097 shares or 0.01% of the stock. Westport Resources Management accumulated 0.01% or 500 shares. The Minnesota-based Disciplined Growth Investors Mn has invested 0.1% in NuVasive, Inc. (NASDAQ:NUVA). Blackrock Inv Mngmt Ltd Company accumulated 0.02% or 231,338 shares. Citadel Advisors Limited Co holds 0.01% or 167,588 shares in its portfolio. Seven Eight Cap Limited Liability Co reported 7,300 shares or 0.15% of all its holdings. Paradigm Capital Mgmt accumulated 0.11% or 15,400 shares. Balyasny Asset Mgmt Limited Liability has 135,600 shares for 0.05% of their US portfolio. Principal Fincl Gp Inc accumulated 360,941 shares or 0.03% of the stock. Cipher Capital Limited Partnership has invested 0.15% of its portfolio in NuVasive, Inc. (NASDAQ:NUVA). Ghost Tree Capital Ltd Liability Company last reported 2.59% of its portfolio in the stock.

Insider Transactions: Since June 15, 2016, the stock had 4 buys, and 5 sales for $322,731 net activity. Another trade for 4,200 shares valued at $244,692 was made by OHALLERAN MICHAEL D on Friday, November 4. On Tuesday, August 23 Hannon Jason sold $170,100 worth of the stock or 2,625 shares. Stafslien Joan also bought $298,400 worth of NuVasive, Inc. (NASDAQ:NUVA) on Monday, October 31. 16,967 shares were bought by Miles Patrick, worth $1.00M. HOWE LESLEY H sold $224,909 worth of NuVasive, Inc. (NASDAQ:NUVA) on Monday, August 1.

Nuvasive, Inc. is a medical device company in the spine market. The company has a market cap of $3.36 billion. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. It has a 82.85 P/E ratio. The Firm offers two product lines: spine surgery products and biologics.

According to Zacks Investment Research, “NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company’s product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Company’s current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.”

NUVA Company Profile

Nuvasive, Inc., incorporated on July 21, 1997, is a medical device firm in the spine market. The Firm focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Firm offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

Another recent and important NuVasive, Inc. (NASDAQ:NUVA) news was published by Fool.com which published an article titled: “Weaker Sales Guidance Pushes NuVasive, Inc. Lower by 10%” on October 26, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>